Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIBIOTIKA study
2026-526995-22-00Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Sep 2026
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of clavulanic acid, amoxicillin, cloxacillin, cefuroxime and dicloxacillin in surgical site infection (SSI) (2 cohorts), sponsored by Central Denmark Region. Primary endpoint: Time above MIC in tissue and plasma. Planned start Sep 2026; status: authorised.
02
Drugs
clavulanic acidamoxicillincloxacillincefuroximedicloxacillin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on 2026-526995-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526995-22-00.